Table 2.
Average Cost and Efficacy of Base-Case Analysis
| Treatment strategy | Average | Incremental | ICER ($/QALY gained) | ||
|---|---|---|---|---|---|
| Cost ($U.S.) | Efficacy (QALY) | Cost | Efficacy | ||
| Usual care | $6,397 | 0.476 | REF | REF | REF |
| First-line adjunctive cannabis | $7,234 | 0.488 | — | — | Dominated |
| Second-line adjunctive cannabis | $7,007 | 0.489 | $610 | 0.013 | $48,594 |
| Third-line adjunctive cannabis | $6,641 | 0.480 | — | — | Ext. dominated |
All costs are in 2017 U.S. dollars. ICERs are calculated referent to the next least costly nondominated treatment option.
ICER, incremental cost-effectiveness ratio; REF, reference value; Ext. dominated, extendedly dominated; QALY, quality-adjusted life-years.